A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial
On June 24, 2020, professor Chim C Lang from Division of Molecular & Clinical Medicine of University of Dundee published a paper titled A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial on European Heart Journal.
The ELISA kit (PIIINP, CEA573Hu) of Cloud-Clone brand was chosed to determine the concentation of PIIINP in this article, we are so proud for supporting the reaserchers.
Patients with type 2 diabetes (T2D) mellitus have double the risk of cardiovascular death (CVD) compared with people without T2D. Heart failure is an important manifestation of diabetic heart disease. Men with diabetes are twice as likely to have heart failure as those without T2D and women with T2D have a fivefold increased risk.We tested the hypothesis that dapagliflflozin may regress left ventricular hypertrophy (LVH) in people with type 2 diabetes (T2D). Dapagliflflozin treatment signifificantly reduced LVM in people with T2D and LVH. This reduction in LVM was accompanied by reductions in systolic BP, body weight, visceral and SCAT, insulin resistance, and hsCRP. The regression of LVM suggests dapagliflflozin can initiate reverse remodelling and changes in left ventricular structure that may partly contribute to the cardio-protective effects of dapagliflflozin.